Ditchcarbon
  • Contact
  1. Organizations
  2. Protheos
Public Profile
Pharmaceutical Preparation Manufacturing
FR
updated 2 months ago

Protheos Sustainability Profile

Company website

Protheos, a leading player in the biotechnology sector, is headquartered in France and operates extensively across Europe. Founded in 2015, the company has rapidly established itself as a pioneer in the development of innovative biopharmaceutical solutions, focusing on advanced therapies and personalised medicine. Protheos is renowned for its unique approach to drug development, leveraging cutting-edge technologies to enhance therapeutic efficacy and patient outcomes. With a commitment to research and development, the company has achieved significant milestones, including collaborations with major pharmaceutical firms and successful clinical trials. As a trusted name in the industry, Protheos continues to push the boundaries of biotechnology, positioning itself at the forefront of medical advancements and contributing to the evolution of healthcare solutions.

DitchCarbon Score

How does Protheos's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

26

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

34

Industry Benchmark

Protheos's score of 26 is lower than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.

41%

Let us know if this data was useful to you

Protheos's reported carbon emissions

In 2024, Protheos reported total carbon emissions of approximately 124,700 kg CO2e, with emissions distributed across various scopes: 1,100 kg CO2e from Scope 1, 1,800 kg CO2e from Scope 2, and a significant 121,800 kg CO2e from Scope 3. This data reflects a slight decrease from 2022, when total emissions were about 128,000 kg CO2e, with similar scope distributions. Protheos has set a near-term reduction target for Scope 2 emissions, aiming for a 20% decrease by 2028, projecting emissions to fall to approximately 1,200 kg CO2e. This commitment underscores the company's proactive approach to mitigating its carbon footprint. The emissions data is not cascaded from any parent organisation, indicating that Protheos independently reports its climate impact. The company continues to focus on enhancing its sustainability practices as part of its broader climate commitments.

How Carbon Intensive is Protheos's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Protheos's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Protheos's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Protheos is in FR, which has a very low grid carbon intensity relative to other regions.

Protheos's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Protheos has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Protheos's Emissions with Industry Peers

C2F Implants

FR
•
Medical, precision and optical instruments, watches and clocks (33)
Updated 9 days ago

Amgen

US
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Astra Zeneca

GB
•
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Sanofi

FR
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Roche Holding AG

CH
•
Pharmaceutical Preparation Manufacturing
Updated 6 days ago

Corin Group Limited

GB
•
Health and social work services (85)
Updated about 1 month ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251114.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
AWS Marketplace logo
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy